Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Impact · against what's priced in

Moderna's surge to $204.60 increases valuation risk by pulling forward the successful readout of the melanoma trial, leaving the stock vulnerable to any imperfections in the upcoming ESMO Madrid data. Merck's price continues to discount the full upside of this oncology platform, while Pfizer's slide reflects its lack of immediate catalysts compared to its mRNA peers.

MRNA−0.20

Challenges what's priced in

The price assumes